• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    2/9/23 11:32:50 AM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    SC 13G/A 1 tv01966-sterisplc.htm SCHEDULE 13G/A sterisplc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  STERIS plc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  G8473T100

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  G8473T100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    138,211

    7.  SOLE DISPOSITIVE POWER

    11,557,426

    8.  SHARED DISPOSITIVE POWER

    408,614

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,966,040

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.99%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    STERIS plc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5960 Heisley Road
    Mentor, OH 44060

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    G8473T100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $STE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    2/14/2022$250.00 → $270.00Market Outperform
    JMP Securities
    More analyst ratings

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Morgan Stanley initiated coverage on Steris with a new price target

      Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00

      5/30/23 7:41:11 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Financials

    Live finance-specific insights

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and President, Healthcare Majors Cary L exercised 12,828 units of Ordinary Shares at a strike of $147.05 and sold $3,208,026 worth of Ordinary Shares (12,828 units at $250.08) (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      5/22/25 4:31:17 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SVP and President, Healthcare Majors Cary L sold $365,532 worth of Ordinary Shares (1,682 units at $217.32), decreasing direct ownership by 13% to 11,372 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      11/27/24 4:30:15 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,251 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      10/2/24 4:37:12 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    SEC Filings

    See more
    • SEC Form 144 filed by STERIS plc (Ireland)

      144 - STERIS plc (0001757898) (Subject)

      5/20/25 4:10:47 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - STERIS plc (0001757898) (Filer)

      5/14/25 4:34:06 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by STERIS plc (Ireland)

      8-K - STERIS plc (0001757898) (Filer)

      3/3/25 5:03:38 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    See more
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care